Purple Biotech Ltd. (PPBT) Stock Score, Valuation & Financial Research

Purple Biotech Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PPBT

Purple Biotech Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 1.23. These figures are a research snapshot, not a buy or sell recommendation.

What Purple Biotech Ltd. does

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Purple Biotech Ltd. is a clinical-stage biotechnology company that focuses on the development of proprietary oncology therapies. The company generates no commercial revenue from product sales and currently funds its operations primarily through the issuance of equity and debt securities, as it continues to advance its research and development pipeline.

Products and services

  • The company's primary product candidate is CAPTN-3, a platform of masked tri-specific antibodies designed to target tumor-associated antigens while simultaneously engaging T cells and NK cells for the treatment of solid tumors.

Brands and product families

  • CAPTN-3 — Lead platform of masked tri-specific antibodies for solid tumors. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party CROs to conduct preclinical and clinical trials. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party CMOs for the manufacturing of its drug candidates. Source

Business relationships and partnerships

  • Converge Bio — A collaboration focused on utilizing AI to accelerate the development of the company's next-generation tri-specific antibody platform. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company competes with numerous entities developing oncology therapies, including those focused on antibody-based treatments and immunotherapy. Source

Business strengths to evaluate

  • Proprietary tri-specific antibody platform (CAPTN-3) Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Need for additional capital to fund research and development Source
  • Dependence on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PPBT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.23
Market capitalization:
169.84K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -24.49M
Free cash flow:
USD -5.54M
Cash:
USD 5.24M
Total debt:
USD 134K
EPS:
USD -2.22

What stands out

  • Free cash flow is USD -5.54M, negative for the stored period.
  • The balance sheet shows USD 5.24M of cash versus USD 134K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 5.1M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PPBT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PPBT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PPBT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PPBT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PPBT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PPBT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.